Primary Membranous Nephropathy (PMN) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Primary Membranous Nephropathy (PMN) Market Outlook

Thelansis's "Primary Membranous Nephropathy (PMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Membranous Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Membranous Nephropathy (PMN) Overview

Primary Membranous Nephropathy (PMN) is a specific, autoimmune-mediated glomerular disease and a leading cause of nephrotic syndrome in non-diabetic adults. Clinically, it presents with massive proteinuria (>3.5 g/day), peripheral edema, hypoalbuminemia, hyperlipidemia, and an increased risk of thromboembolic complications, including renal vein thrombosis.

The pathophysiology is characterized by subepithelial deposition of IgG4 autoantibodies and complement complexes (C5b-9 membrane attack complex) along the glomerular basement membrane, leading to podocyte injury and disruption of the filtration barrier.

Modern classification of PMN is based on its molecular drivers. Approximately 70-80% of cases are associated with anti-PLA2R (M-type phospholipase A2 receptor) antibodies, while ~1-5% are linked to THSD7A antibodies. This molecular understanding has significantly transformed disease management, enabling non-invasive diagnosis through serological testing and the use of antibody titers for disease monitoring and risk stratification.

PMN predominantly affects adults, with peak incidence in middle-aged and older populations. Diagnosis is supported by serology and, where required, kidney biopsy.

Treatment strategies include supportive therapy (ACE inhibitors, ARBs, statins, diuretics) and immunosuppressive regimens, including corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Notably, B-cell depleting therapies such as rituximab have become central to modern management, enabling targeted immunological remission.

Despite advances, PMN remains a chronic, relapsing condition, with ongoing risk of progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD), driving continued need for novel targeted therapies.

Key Highlights

• The diagnosed prevalent PMN population in the United States is estimated at 86,410 in 2025, increasing to 97,845 by 2035, reflecting steady disease burden growth.
• The incident diagnosed population grows from 3,297 cases in 2025 to 3,546 cases by 2035, indicating gradual increase in diagnosis rates.
• 34,996 female vs 51,414 male cases in 2025, widening further by 2035 (39,627 females vs 58,218 males).
• The average age of patients is 48 years, with the highest disease burden concentrated in ≥55 years age group.
• The disease is chronic and progressive, with a significant proportion of patients requiring long-term immunosuppressive therapy, contributing to sustained treatment demand.

Market Overview

• The PMN treatment market is valued at $622M in 2025, projected to reach $3.18Bn by 2035, representing a robust CAGR of 17.8% over the forecast period.
• Early-stage market (2025-2027) is dominated by conventional therapies, including: ACE inhibitors / ARBs, Corticosteroids (prednisone, methylprednisolone), Immunosuppressants (cyclosporine, tacrolimus, MMF), Rituximab and IVIG
• By 2035, novel biologics and targeted therapies dominate the market, accounting for the majority of revenue share, significantly shifting the treatment paradigm.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Excyte Biopharma Ltd
• Climb Bio, Inc.
• Cerium Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• argenx
• BioRay Pharmaceutical Co., Ltd.
• Shanghai JMT-Bio Inc.
• Beijing Mabworks Biotech Co., Ltd.
• Biogen
• Guangdong Hengrui Pharmaceutical Co., Ltd
• BeOne Medicines
• Hoffmann-La Roche
• Everest Medicines (China) Co.,Ltd.
• Nkarta, Inc.
• Walden Biosciences
• Apellis Pharmaceuticals, Inc.
• Alpine Immune Sciences, Inc.
• Vera Therapeutics, Inc.
• Reistone Biopharma Company Limited